Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

KIDNEY CANCER

Hypoxia-inducible factor 2 inhibitors show promise in advanced kidney cancer

Nature Reviews Urology volume 18, pages 516–517 (2021)Cite this article

Subjects

A new phase I clinical trial has demonstrated that belzutifan provides a route to sustained inhibition of hypoxia-inducible factor 2α in humans that is well tolerated and could be useful in the treatment of advanced clear cell kidney cancer.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Barata, P. C. & Rini, B. I. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J. Clin. 67, 507–524 (2017).

    Article  Google Scholar 

  2. Semenza, G. L. Pharmacologic targeting of hypoxia-inducible factors. Annu. Rev. Pharmacol. Toxicol. 59, 379–403 (2019).

    Article  CAS  Google Scholar 

  3. Chen, W. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112–117 (2016).

    Article  CAS  Google Scholar 

  4. Scheuermann, T. H. et al. Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor. Proc. Natl Acad. Sci. USA 106, 450–455 (2009).

    Article  CAS  Google Scholar 

  5. Courtney, K. D. et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J. Clin. Oncol. 36, 867–874 (2018).

    Article  CAS  Google Scholar 

  6. Xu, R. et al. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a hypoxia-inducible factor 2α (HIF-2α) inhibitor for the treatment of clear cell renal cell carcinoma. J. Med. Chem. 62, 6876–6893 (2019).

    Article  CAS  Google Scholar 

  7. Choueiri, T. K. et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat. Med. 27, 802–805 (2021).

    Article  CAS  Google Scholar 

  8. Morais, C., Johnson, D. W., Vesey, D. A. & Gobe, G. C. Functional significance of erythropoietin in renal cell carcinoma. BMC Cancer 13, 14 (2013).

    Article  CAS  Google Scholar 

  9. Courtney, K. D. et al. HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin. Cancer Res. 26, 793–803 (2020).

    Article  CAS  Google Scholar 

  10. Wu, D. et al. Bidirectional modulation of HIF-2 activity through chemical ligands. Nat. Chem. Biol. 15, 367–376 (2019).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

P.H.M. acknowledges the support of the Wellcome Trust (no. 19710), the NIHR Cambridge Biomedical Research Centre and the Rosetrees Trust (no. G102721).

Author information

Authors and Affiliations

  1. Cambridge Institute for Medical Research, The Keith Peters Building, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK

    Natalie Burrows & Patrick H. Maxwell

  2. Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK

    Natalie Burrows & Patrick H. Maxwell

Authors
  1. Natalie Burrows
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick H. Maxwell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick H. Maxwell.

Ethics declarations

Competing interests

P.H.M. is a scientific founder and equity holder of ReOx Ltd and has received speaker honoraria from Fibrogen and Astellas. He has also undertaken consultancy work for Mission Therapeutics. N.B. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Burrows, N., Maxwell, P.H. Hypoxia-inducible factor 2 inhibitors show promise in advanced kidney cancer. Nat Rev Urol 18, 516–517 (2021). https://doi.org/10.1038/s41585-021-00487-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-021-00487-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing